Palatin Technologies (NYSE:PTN) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of Palatin Technologies (NYSE:PTN) in a research note issued on Tuesday. The brokerage set a “sell” rating on the stock.

Palatin Technologies Price Performance

NYSE PTN opened at $0.09 on Tuesday. The firm has a market cap of $2.45 million, a P/E ratio of -0.06 and a beta of 0.94. Palatin Technologies has a 1 year low of $0.09 and a 1 year high of $2.48.

About Palatin Technologies

Palatin Technologies, Inc, a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company’s lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.